Flynn, N. M. et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654–665 (2005).

PubMed  Google Scholar 

Houser, K. V. et al. Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: a first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. EClinicalMedicine 48, 101477 (2022).

PubMed  PubMed Central  Google Scholar 

Leggat, D. J. et al. Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science 378, eadd6502 (2022).

CAS  PubMed  PubMed Central  Google Scholar 

Pitisuttithum, P. et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661–1671 (2006).

CAS  PubMed  Google Scholar 

Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).

CAS  PubMed  Google Scholar 

Hunter, M., Yuan, P., Vavilala, D. & Fox, M. Optimization of protein expression in mammalian cells. Curr. Protoc. Protein Sci. 95, e77 (2019).

PubMed  Google Scholar 

Schmieder, V. et al. Towards maximum acceleration of monoclonal antibody development: leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable pool. J. Biotechnol. 349, 53–64 (2022).

CAS  PubMed  Google Scholar 

Bolisetty, P., Tremml, G., Xu, S. & Khetan, A. Enabling speed to clinic for monoclonal antibody programs using a pool of clones for IND-enabling toxicity studies. MAbs 12, 1763727 (2020).

PubMed  PubMed Central  Google Scholar 

Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).

CAS  PubMed  Google Scholar 

Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).

CAS  PubMed  Google Scholar 

Riddler, S. A. et al. High frequency of chronic urticaria following an investigational HIV-1 BG505 MD39.3 trimer mRNA vaccine in a phase 1, randomized, open-label clinical trial (HVTN 302). Ann. Intern. Med. 10, 02701 (2025).

Willis, J. R. et al. Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans. Science 21, eadr8382 (2025).

Kulkarni, S. S. et al. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology 385, 505–520 (2009).

CAS  PubMed  Google Scholar 

Sharma, S. K. et al. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep. 11, 539–550 (2015).

CAS  PubMed  PubMed Central  Google Scholar 

Sanders, R. W. et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 76, 8875–8889 (2002).

CAS  PubMed  PubMed Central  Google Scholar 

Sanders, R. W. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).

CAS  PubMed  PubMed Central  Google Scholar 

Klasse, P. J. et al. Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J. Virol. 87, 9873–9885 (2013).

CAS  PubMed  PubMed Central  Google Scholar 

Guenaga, J. et al. Structure-guided redesign increases the propensity of HIV Env to generate highly stable soluble trimers. J. Virol. 90, 2806–2817 (2015).

PubMed  Google Scholar 

Guenaga, J. et al. Glycine substitution at helix-to-coil transitions facilitates the structural determination of a stabilized subtype C HIV envelope glycoprotein. Immunity 46, 792–803.e793 (2017).

CAS  PubMed  PubMed Central  Google Scholar 

Kwon, Y. D. et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat. Struct. Mol. Biol. 22, 522–531 (2015).

PubMed  PubMed Central  Google Scholar 

Nguyen, H. T., Alsahafi, N., Finzi, A. & Sodroski, J. G. Effects of the SOS (A501C/T605C) and DS (I201C/A433C) disulfide bonds on HIV-1 membrane envelope glycoprotein conformation and function. J. Virol. 93, 00303 (2019).

Berndsen, Z. T. et al. Visualization of the HIV-1 Env glycan shield across scales. Proc. Natl Acad. Sci. USA 117, 28014–28025 (2020).

CAS  PubMed  PubMed Central  Google Scholar 

Stewart-Jones, G. B. et al. Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G. Cell 165, 813–826 (2016).

CAS  PubMed  PubMed Central  Google Scholar 

Dubrovskaya, V. et al. Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response. PLoS Pathog. 13, e1006614 (2017).

PubMed  PubMed Central  Google Scholar 

Dubrovskaya, V. et al. Vaccination with glycan-modified HIV NFL envelope trimer-liposomes elicits broadly neutralizing antibodies to multiple sites of vulnerability. Immunity 51, 915–929.e917 (2019).

CAS  PubMed  PubMed Central  Google Scholar 

Caniels, T. G. et al. Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site. Sci. Immunol. 9, eadk9550 (2024).

CAS  PubMed  PubMed Central  Google Scholar 

Crooks, E. T. et al. Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction. Virology 505, 193–209 (2017).

CAS  PubMed  Google Scholar 

LaBranche, C. C. et al. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. PLoS Pathog. 14, e1007431 (2018).

PubMed  PubMed Central  Google Scholar 

Zhou, T. et al. Quantification of the impact of the HIV-1-glycan shield on antibody elicitation. Cell Rep. 19, 719–732 (2017).

CAS  PubMed  PubMed Central  Google Scholar 

Pritchard, L. K. et al. Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nat. Commun. 6, 7479 (2015).

CAS  PubMed  Google Scholar 

Wolfe, L. S. et al. Development of a platform-based approach for the clinical production of HIV gp120 envelope glycoprotein vaccine candidates. Vaccine 39, 3852–3861 (2021).

CAS  PubMed  Google Scholar 

Lee, J. H. et al. A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic beta-hairpin structure. Immunity 46, 690–702 (2017).

CAS  PubMed  PubMed Central  Google Scholar 

Dey, A. K. et al. cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. Biotechnol. Bioeng. 115, 885–899 (2018).

CAS  PubMed  Google Scholar 

Cupo, A. et al. Optimizing the production and affinity purification of HIV-1 envelope glycoprotein SOSIP trimers from transiently transfected CHO cells. PLoS One 14, e0215106 (2019).

CAS  PubMed  PubMed Central  Google Scholar 

Sanders, R. W. et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76, 7293–7305 (2002).

CAS  PubMed  PubMed Central  Google Scholar 

Alderton, M. R., Gray, P. J. & Prolf, D. F. Genetic vaccination: can plasmid DNA deliver its expectations? J. Milit. Veterans’ Health 10, 95681947 (2001).

Davis, H. L. & McCluskie, M. J. DNA vaccines for viral diseases. Microbes Infect. 1, 7–21 (1999).

CAS  PubMed  Google Scholar 

Khan, A. S. Characterization and qualification of cell substrates for manufacturing viral vaccines in the United States. BioProcess J. 8, 8–12 (2009).

Google Scholar 

Shroff, K. E. et al. Induction of HSV-gD2 specific CD4(+) cells in Peyer’s patches and mucosal antibody responses in mice following DNA immunization by both parenteral and mucosal administration. Vaccine 18, 222–230 (1999).

CAS  PubMed  Google Scholar 

Baboo, S. et al. DeGlyPHER: an ultrasensitive method for the analysis of viral spike N-glycoforms. Anal. Chem. 93, 13651–13657 (2021).

Brouwer, P. J. M. et al. Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. NPJ Vaccines 6, 24 (2021).

CAS  PubMed  PubMed Central